These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 30965069)

  • 21. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Vali Y; Lee J; Boursier J; Spijker R; Löffler J; Verheij J; Brosnan MJ; Böcskei Z; Anstee QM; Bossuyt PM; Zafarmand MH;
    J Hepatol; 2020 Aug; 73(2):252-262. PubMed ID: 32275982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level.
    Gabriel-Medina P; Ferrer-Costa R; Ciudin A; Augustin S; Rivera-Esteban J; Pericàs JM; Selva DM; Rodriguez-Frias F
    Intern Emerg Med; 2024 Apr; 19(3):745-756. PubMed ID: 37952070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
    Caussy C; Ajmera VH; Puri P; Hsu CL; Bassirian S; Mgdsyan M; Singh S; Faulkner C; Valasek MA; Rizo E; Richards L; Brenner DA; Sirlin CB; Sanyal AJ; Loomba R
    Gut; 2019 Oct; 68(10):1884-1892. PubMed ID: 30567742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards collaborative management of non-alcoholic fatty liver disease: a 'real-world' pathway for fibrosis risk assessment in primary care.
    Hayward KL; McKillen BJ; Horsfall LU; McIvor C; Liew K; Sexton J; Johnson AL; Irvine KM; Valery PC; McPhail SM; Britton LJ; Rosenberg W; Weate I; Williams S; Powell EE
    Intern Med J; 2022 Oct; 52(10):1749-1758. PubMed ID: 34139066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct comparison of the specialised blood fibrosis tests FibroMeter
    Guillaume M; Moal V; Delabaudiere C; Zuberbuhler F; Robic MA; Lannes A; Metivier S; Oberti F; Gourdy P; Fouchard-Hubert I; Selves J; Michalak S; Peron JM; Cales P; Bureau C; Boursier J
    Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1214-1222. PubMed ID: 31617224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface.
    McPherson S; Jarvis H; McGonigle J; Bedlington J; Dean J; Hallsworth K; Hanon E; Liddle T; Luvai A; Mansour D; Patel P; Renwick L; Teare D; Tanney C; Anstee Q
    BMJ Open Gastroenterol; 2023 Feb; 10(1):. PubMed ID: 36754448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Aykut UE; Akyuz U; Yesil A; Eren F; Gerin F; Ergelen R; Celikel CA; Yilmaz Y
    Scand J Gastroenterol; 2014 Nov; 49(11):1343-8. PubMed ID: 25259621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia.
    Serra-Burriel M; Graupera I; Torán P; Thiele M; Roulot D; Wai-Sun Wong V; Neil Guha I; Fabrellas N; Arslanow A; Expósito C; Hernández R; Lai-Hung Wong G; Harman D; Darwish Murad S; Krag A; Pera G; Angeli P; Galle P; Aithal GP; Caballeria L; Castera L; Ginès P; Lammert F;
    J Hepatol; 2019 Dec; 71(6):1141-1151. PubMed ID: 31470067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
    Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.
    Chan WK; Nik Mustapha NR; Mahadeva S
    Hepatol Int; 2015 Oct; 9(4):594-602. PubMed ID: 25788185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
    Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
    Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
    McPherson S; Hardy T; Dufour JF; Petta S; Romero-Gomez M; Allison M; Oliveira CP; Francque S; Van Gaal L; Schattenberg JM; Tiniakos D; Burt A; Bugianesi E; Ratziu V; Day CP; Anstee QM
    Am J Gastroenterol; 2017 May; 112(5):740-751. PubMed ID: 27725647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective study of a case-finding algorithm to detect NAFLD with advanced fibrosis in primary care patients.
    Fox RK; Chu JN; Goldman ML; Islam KB; Brandman D
    Hepatol Commun; 2023 Feb; 7(2):e0024. PubMed ID: 36724121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
    Önnerhag K; Hartman H; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
    [No Abstract]   [Full Text] [Related]  

  • 39. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.
    Li Q; Lu C; Li W; Huang Y; Chen L
    Oncotarget; 2017 Apr; 8(17):28641-28649. PubMed ID: 28415736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Not Available].
    Hansen CD; Lindvig KP; Grønbæk H; Gluud LL; Thiele M; Krag A
    Ugeskr Laeger; 2022 Oct; 184(42):. PubMed ID: 36305262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.